Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	61.33	93.45	72.2	183.61	192.8	179.43
Short-Term Investments	333.82	365.54	455.42	283.99	644.56	355.41
Cash & Cash Equivalents	395.15	458.99	527.61	467.59	837.36	534.83
Cash Growth	-17.94%	-13.01%	12.84%	-44.16%	56.56%	16.10%
Other Current Assets	0.21	0.13	1.21	3.73	7.77	9.74
Total Current Assets	395.36	459.12	528.82	471.32	845.13	544.58
Property, Plant & Equipment	160.41	163.18	196.43	181.02	160.14	100.94
Long-Term Investments	15.12	3.65	76.47	382.38	207.95	63.21
Goodwill and Intangibles	0	0	0	0	0	0.15
Other Long-Term Assets	15.45	16.9	19.86	16.11	14.62	8.92
Total Long-Term Assets	190.99	183.72	292.76	579.51	382.7	173.23
Total Assets	586.35	642.84	821.58	1,051	1,228	717.8
Accounts Payable	5.78	5.9	13.89	10.26	10.39	9.25
Deferred Revenue	0.09	0.09	0.1	0.16	38.99	0
Other Current Liabilities	25.03	31.1	39.74	37.5	44.94	23.83
Total Current Liabilities	30.89	37.08	53.73	47.91	94.32	33.08
Other Long-Term Liabilities	94.09	93.53	100.97	77.72	53.89	55.7
Total Long-Term Liabilities	94.09	93.53	100.97	77.72	53.89	55.7
Total Liabilities	124.98	130.6	154.7	125.63	148.21	88.78
Retained Earnings	-1,627.23	-1,562.23	-1,234.97	-894.55	-646.34	-396.12
Comprehensive Income	-0.93	-0.96	-9.93	-2.57	0.27	1.15
Shareholders' Equity	461.37	512.23	666.88	925.2	1,080	629.02
Net Cash / Debt	395.15	458.99	527.61	467.59	837.36	534.83
Net Cash / Debt Growth	1.84%	-13.01%	12.84%	-44.16%	56.56%	16.10%
Net Cash Per Share	2.34	2.92	3.69	3.44	6.96	5.29
Working Capital	364.47	422.04	475.1	423.42	750.81	511.5
Book Value Per Share	2.73	3.26	4.66	6.81	8.97	6.22

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).